GLG News by Tykerb Prescribers (US)

Jeffrey Bubis, Partner, Hematologist and Medical Oncologist

Jeffrey BubisPartner, Hematologist and Medical OncologistINTEGRATED COMMUNITY ONCOLOGY NETWORK, LLC What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

New Agents in Melanoma Show Advances at ASCO

June 9, 2011

Drugs Show Promise Slowing Advanced Melanoma | www.nytimes.com

Data presented a the ASCO meeting showed an overall survival benefit for patients receiving Roche/Genentech's vemurafenib and Bristol-Myers Squibb/s Yervoy (ipilimumab) when these agents were compared to standard of care therapy.

Jeffrey Bubis, Partner, Hematologist and Medical Oncologist

Jeffrey BubisPartner, Hematologist and Medical OncologistINTEGRATED COMMUNITY ONCOLOGY NETWORK, LLC What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

Long term Revlimid (Celgene) may cause cancer.

December 7, 2010

Celgene shares plummet on Revlimid malignancy data | www.reuters.com

Data presented at the American Society of Hematology Convention suggests the possibility that long term use of Revlimid may be a associated with the development of secondary malignancies.

Jeffrey Bubis, Partner, Hematologist and Medical Oncologist

Jeffrey BubisPartner, Hematologist and Medical OncologistINTEGRATED COMMUNITY ONCOLOGY NETWORK, LLC What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

Outlook is better for Provenge

November 20, 2010

Medicare Panel Supports Use of Provenge in FDA-Approved Population | blogs.wsj.com

A Medicare advisory panel gave a lukewarm endorsement to Provenge. Final Medicare opinion is pending.

Jeffrey Bubis, Partner, Hematologist and Medical Oncologist

Jeffrey BubisPartner, Hematologist and Medical OncologistINTEGRATED COMMUNITY ONCOLOGY NETWORK, LLC What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

Algeta Begins Enrolling Patients in Prostate Cancer Study

December 21, 2009

Algeta begins phase-III trial of Alpharadin in male patient with castration-resistant prostate cancer | www.pharmabiz.com

The ALSYMPCA (ALpharadin in SYMptomatic Prostate CAncer) study is a double-blind, randomized, controlled trial that enrols patients to be randomized to receive Alpharadin (radium-223 chloride) plus best standard of care or placebo plus best standard of care.  Approximately 750 patients are expected to be enrolled in this multi-institution trial with. recruitment expected to be complete by the second half of 2010. The primary outcome to be measured is overall survival.

Jeffrey Bubis, Partner, Hematologist and Medical Oncologist

Jeffrey BubisPartner, Hematologist and Medical OncologistINTEGRATED COMMUNITY ONCOLOGY NETWORK, LLC What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

An Overall Survival Benefit In Chronic Lymphocytic Leukemia (CLL)

December 10, 2009

Roche presents pivotal phase-III study of CLL8 at ASH 2009 | www.pharmabiz.com

The CLL8 Trial demonstrated that FCR (Fludarabine, Cyotxan, Rituxan) provided a modest, but statistically significant survival benefit over FC (Fludarabine, Cytoxan) in patients with chronic lymphocytic leukemia.

Jeffrey Bubis, Partner, Hematologist and Medical Oncologist

Jeffrey BubisPartner, Hematologist and Medical OncologistINTEGRATED COMMUNITY ONCOLOGY NETWORK, LLC What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

CCL8 Data Coming to ASH

December 8, 2009

Roche to present CLL8's pivotal phase-III study results at ASH in New Orleans | www.pharmabiz.com

Updated results from the CCL8 trial of Fludarabine and Cytoxan (FC) vs. Fludarabine, Cytoxan, and Rituxan (FCR) will be released at the American Society of Hematology Meeting (ASH) in New Orleans.

Jeffrey Bubis, Partner, Hematologist and Medical Oncologist

Jeffrey BubisPartner, Hematologist and Medical OncologistINTEGRATED COMMUNITY ONCOLOGY NETWORK, LLC What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

Teva Develops a Neupogen Biosimilar

December 2, 2009

Teva Announces the Submission of a Biologics License Application (BLA) for XM02 for the Treatment of Chemotherapy-Induced Neutropenia | www.pipelinereview.com

Teva Pharmaceutical announced the submission of a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for XM02, a granulocyte colony-stimulating factor (G-CSF) for the reduction in the duration of severe neutropenia and the incidence of febrile neutropenia in patients treated with established myelosuppressive chemotherapy for cancer.

Jeffrey Bubis, Partner, Hematologist and Medical Oncologist

Jeffrey BubisPartner, Hematologist and Medical OncologistINTEGRATED COMMUNITY ONCOLOGY NETWORK, LLC What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

New Drug For Resistant CML

November 23, 2009

US FDA accepts ChemGenex's Omapro NDA filing to treat CML, grants priority review status | www.pharmabiz.com

A new drug by ChemGenex, Omapro, presents a new option for the treatment of TKI-resistant CML patients.

Jon StrasserAssistant Professor of Radiation OncologyTHOMAS JEFFERSON UNIVERSITY What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

Particle Beam Technology - Costly and a limited utility

October 26, 2009

Particle Beam Radiation Therapy published by AHRQ | effectivehealthcare.ahrq.gov

Over the last several years, there has been an increased interest in the US in particle beam therapy as the costs have come down and large manufacturers have become more efficient in installing these centers. In addition, private companies have made a business model of building proton centers - mostly by treating prostate cancer.Protons are incredibly useful in specific diseases - ie ocular melanoma, pediatric cancers, but are too costly without proven benefit for our health care system.

Jeffrey Bubis, Partner, Hematologist and Medical Oncologist

Jeffrey BubisPartner, Hematologist and Medical OncologistINTEGRATED COMMUNITY ONCOLOGY NETWORK, LLC What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

Genentech and Dako Collaborate To Increase Herceptin Use In Gastric Cancer

August 18, 2009

Dako enters collaboration with Genentech on diagnostic tests for patients with stomach cancer | www.pipelinereview.com

Phase III data presented at ASCO in 2009 demonstrated a benefit for patients with HER-2 overexpressing gastric cancer who received Herceptin.  Dako, the developer of the HercepTest and Genetech, the manufacturer of Herceptin, have joined forces to increase HER2 testing and Herceptin utilization.

Page : 123456789Next1 to 10 of 83

Leading institutions connect with members of the Healthcare councils through GLG

Most Popular Healthcare News